Deborah Lawson

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 440 citations · Full text

Medicine, Cancer Biology, Oncology +8

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao et al. · Molecular Cancer Therapeutics · 2016 · 157 citations · Full text

Medicine, Oncology, Pharmacology +17

Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress

Lucy A. Young, Lenka Oplustil O'Connor, Christelle de Renty et al. · Cancer Research · 2019 · 71 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth et al. · Clinical Cancer Research · 2020 · 69 citations

Medicine, Oncology, Pharmacology +13

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Zebin Wang, Shaun Grosskurth, Tony Cheung et al. · Cancer Research · 2018 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17